HAI advocates for access to essential treatments that satisfy the priority health care needs of a population. We monitor European Union (EU) trade agreements and negotiations, highlighting inconsistencies between EU commitments on development, and external trade policies that could damage public health in developing countries. We work with civil society partners across the world to prevent policies that harm access for some of the world’s poorest citizens.
Today, pharmaceutical research and development is largely driven by monopoly incentives, which are not always aligned with public health priorities. As part of our goal to improve access to medicines, HAI campaigns for alternative models for medical innovation to address real therapeutic needs, and neglected and rare diseases.
HAI Europe raises awareness amongst policymakers and the public about the importance of competition from generic medicines in promoting access to affordable treatment. Generic medicines can cost significantly less than branded medicines, which has an impact on the affordability of medicines for citizens, health insurers, and state health budgets. We monitor EU trade policies to make sure that competition from generic medicines is not inhibited.
“Supported [in part] by a grant from the Open Society Foundations.”